Men’s blood has higher levels of a key enzyme used by the Coronavirus to infect cells, study

ACE2 is found in the heart, kidneys and it is thought to play a role in how the infection progresses into the lungs.

Reuters May 11, 2020 12:23:46 IST
Men’s blood has higher levels of a key enzyme used by the Coronavirus to infect cells, study

Men’s blood has higher levels than women’s of a key enzyme used by the new coronavirus to infect cells, the results of a big European study showed on Monday — a finding which may help explain why men are more vulnerable to infection with COVID-19.

Angiotensin-converting enzyme 2 (ACE2) is found in the heart, kidneys and other organs. In COVID-19, the respiratory disease caused by the novel coronavirus, it is thought to play a role in how the infection progresses into the lungs.

Mens blood has higher levels of a key enzyme used by the Coronavirus to infect cells study

Death and infection tolls point to men being more likely than women to contract the disease and to suffer severe or critical complications if they do.

The study, published in the European Heart Journal, also found that widely-prescribed drugs called ACE inhibitors or angiotensin receptor blockers (ARBs) did not lead to higher ACE2 concentrations and should therefore not increase the COVID-19 risk for people taking them.

ACE inhibitors and ARBs are widely prescribed to patients with congestive heart failure, diabetes or kidney disease. The drugs account for billions of dollars in prescription sales worldwide.

“Our findings do not support the discontinuation of these drugs in COVID-19 patients,” said Adriaan Voors, a professor of cardiology at the University Medical Center (UMC) Groningen in The Netherlands, who co-led the study.

The COVID-19 pandemic has infected more than four million people worldwide and killed almost 277,000, according to a Reuters tally. Death and infection tolls point to men being more likely than women to contract the disease and to suffer severe or critical complications if they do.

Analysing thousands of men and women, Voors’ team measured ACE2 concentrations in blood samples taken from more than 3,500 heart failure patients from 11 European countries.

The study had started before the coronavirus pandemic, the researchers said, and so did not include patients with COVID-19.

But when other research began to point to ACE2 as key to the way the new coronavirus gets into cells, Voors and his team saw important overlaps with their study.

“When we found that one of the strongest biomarkers, ACE2, was much higher in men than in women, I realised that this had the potential to explain why men were more likely to die from COVID-19 than women,” said Iziah Sama, a doctor at UMC Groningen who co-led the study.

ACE2 is a receptor on the surface of cells which binds to the new coronavirus and allows it to enter and infect cells.

Sama and Voors noted that as well as in the lung, ACE2 is found in the heart, kidneys, in tissues lining blood vessels, and in particularly high levels in the testes.

They said its presence in the testes might partially explain higher ACE2 concentrations in men, and why men are more vulnerable to COVID-19.

Updated Date:

also read

WATCH: Chinese citizens protest against Zero Covid policy, clash with police in Guangzhou
World

WATCH: Chinese citizens protest against Zero Covid policy, clash with police in Guangzhou

Even as China is ravaged by the Covid-19 pandemic, the Chinese government has chosen to deal with the crisis with a series of stringent methods, including a rather harsh lockdown, as part of its Zero Covid policy

WATCH: Uyghurs condemn China's Zero Covid policy
World

WATCH: Uyghurs condemn China's Zero Covid policy

The hardships caused by the Zero Covid policy led to widespread protests across China in recent weeks that forced the Chinese government to relax some of the restrictions put in place to fight the Covid-19 pandemic

Bharat Biotech’s Intranasal COVID-19 vaccine gets CDSCO approval
Health

Bharat Biotech’s Intranasal COVID-19 vaccine gets CDSCO approval

iNCOVACC is the world’s first Intranasal vaccine for COVID to receive approval for the primary 2-dose schedule, and heterologous booster dose